Corvus Pharmaceuticals
CRVS
37 hedge funds and large institutions have $18.9M invested in Corvus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.
900% more call options, than puts
Call options by funds: $10K | Put options by funds: $1K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
4% more capital invested
Capital invested by funds: $18.1M → $18.9M (+$775K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.25% less ownership
Funds ownership: 45.9% → 44.65% (-1.3%)
12% less funds holding
Funds holding: 42 → 37 (-5)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| 1 |
Millennium Management
New York
|
+$101K |
| 2 |
Morgan Stanley
New York
|
+$21.5K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$19.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.93K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$111K |
| 2 |
Two Sigma Investments
New York
|
-$60.2K |
| 3 |
Two Sigma Advisers
New York
|
-$57K |
| 4 |
CA
CHI Advisors
New York
|
-$35.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$16.7K |
CRVS Hedge Fund Activity: Q1 2023 in Review
37 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2023, worth a combined $18.9M — up 4.3% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CRVS and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Millennium Management, adding an estimated $101K. The largest seller was Renaissance Technologies, cutting an estimated $111K.
- 37 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2023, down from 42 in Q4 2022.
- Funds reported $18.9M of Corvus Pharmaceuticals stock for Q1 2023, up 4.3% quarter-over-quarter.
- 2 funds opened new Corvus Pharmaceuticals positions in Q1 2023 and 6 closed out, a net change of -4 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2023 was Millennium Management, an estimated $101K added.
- The largest Corvus Pharmaceuticals seller in Q1 2023 was Renaissance Technologies, an estimated $111K sold.
Based on aggregated 13F filings for Q1 2023.